Equities research analysts expect Apollo Endosurgery (NASDAQ:APEN) to report earnings of ($0.40) per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Apollo Endosurgery’s earnings, with estimates ranging from ($0.45) to ($0.35). Apollo Endosurgery posted earnings of ($0.77) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 48.1%. The firm is expected to issue its next quarterly earnings report after the market closes on Thursday, May 3rd.

On average, analysts expect that Apollo Endosurgery will report full year earnings of ($1.41) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.35). For the next financial year, analysts anticipate that the company will post earnings of ($1.01) per share, with EPS estimates ranging from ($1.13) to ($0.89). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Apollo Endosurgery.

Apollo Endosurgery (NASDAQ:APEN) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.08). Apollo Endosurgery had a negative return on equity of 64.48% and a negative net margin of 42.35%. The firm had revenue of $16.14 million for the quarter, compared to analyst estimates of $16.64 million.

Several equities research analysts have issued reports on APEN shares. Roth Capital set a $10.00 price target on shares of Apollo Endosurgery and gave the stock a “buy” rating in a research note on Thursday, January 4th. Zacks Investment Research cut shares of Apollo Endosurgery from a “hold” rating to a “sell” rating in a research note on Tuesday, March 6th. Northland Securities reaffirmed a “buy” rating and set a $12.00 price target on shares of Apollo Endosurgery in a research note on Thursday, February 8th. Piper Jaffray started coverage on shares of Apollo Endosurgery in a research note on Friday, April 13th. They set an “overweight” rating and a $8.00 price target on the stock. Finally, ValuEngine raised shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $9.15.

Apollo Endosurgery stock opened at $5.90 on Wednesday. Apollo Endosurgery has a 12-month low of $3.55 and a 12-month high of $9.58. The company has a current ratio of 2.23, a quick ratio of 1.68 and a debt-to-equity ratio of 0.67.

In related news, Director Matthew S. Crawford bought 4,038 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The shares were acquired at an average cost of $6.20 per share, with a total value of $25,035.60. Following the completion of the transaction, the director now owns 53,715 shares of the company’s stock, valued at $333,033. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 52.80% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in APEN. Russell Investments Group Ltd. acquired a new stake in shares of Apollo Endosurgery in the third quarter worth approximately $1,288,000. JPMorgan Chase & Co. acquired a new position in Apollo Endosurgery during the third quarter valued at approximately $119,000. Stonepine Capital Management LLC lifted its position in Apollo Endosurgery by 8.3% during the fourth quarter. Stonepine Capital Management LLC now owns 2,560,314 shares of the biotechnology company’s stock valued at $14,338,000 after buying an additional 195,607 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Apollo Endosurgery during the fourth quarter valued at approximately $126,000. Finally, Ardsley Advisory Partners lifted its position in Apollo Endosurgery by 53.2% during the fourth quarter. Ardsley Advisory Partners now owns 28,800 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 10,000 shares in the last quarter. 31.20% of the stock is currently owned by institutional investors and hedge funds.

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope.

Get a free copy of the Zacks research report on Apollo Endosurgery (APEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.